BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 506 filers reported holding BIO-TECHNE CORP in Q2 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,956,639 | -2.6% | 36,220 | -11.5% | 0.40% | -1.7% |
| Q1 2023 | $3,035,855 | -10.5% | 40,920 | 0.0% | 0.40% | -11.5% |
| Q4 2022 | $3,391,450 | +16.7% | 40,920 | +300.0% | 0.45% | +15.2% |
| Q3 2022 | $2,905,000 | -18.1% | 10,230 | 0.0% | 0.39% | -14.9% |
| Q2 2022 | $3,546,000 | -20.0% | 10,230 | 0.0% | 0.46% | +5.0% |
| Q1 2022 | $4,430,000 | -16.3% | 10,230 | 0.0% | 0.44% | -6.8% |
| Q4 2021 | $5,292,000 | +6.8% | 10,230 | 0.0% | 0.47% | +1.5% |
| Q3 2021 | $4,957,000 | +41.9% | 10,230 | +31.8% | 0.47% | +90.2% |
| Q2 2021 | $3,494,000 | +17.9% | 7,760 | 0.0% | 0.24% | +9.9% |
| Q1 2021 | $2,964,000 | +188.0% | 7,760 | +139.5% | 0.22% | +205.5% |
| Q4 2020 | $1,029,000 | +28.1% | 3,240 | 0.0% | 0.07% | +17.7% |
| Q3 2020 | $803,000 | -6.2% | 3,240 | 0.0% | 0.06% | +6.9% |
| Q2 2020 | $856,000 | +39.4% | 3,240 | 0.0% | 0.06% | +18.4% |
| Q1 2020 | $614,000 | -13.6% | 3,240 | 0.0% | 0.05% | +6.5% |
| Q4 2019 | $711,000 | +5.2% | 3,240 | 0.0% | 0.05% | +7.0% |
| Q2 2019 | $676,000 | – | 3,240 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |